Pharma BD Deal Intelligence
Takeda's ~$632M bet on TiGenix's stem-cell therapy Alofisel collapsed: confirmatory trial failed, ~$500M impairment taken, and the drug was pulled from the EU (2024) and Japan (2026) markets.
Full analysis, sources & comparables →Takeda's EUR 1.78-a-share offer represents an 82% premium over TiGenix's pre-news close; Phase III data showed half of Cx601 patients went into remission…
Takeda's Alofisel acquisition pays off in Japan with the first allogeneic stem cell therapy approval in the country, validating the GI franchise expansion…
Takeda announces it will not pursue US regulatory approval for Alofisel following ADMIRE-CD II failure and will wind down commercialization in most markets,…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Takeda announced cash tender offer for TiGenix at EUR 1.78/share (~EUR 520M / ~$640M) on January 5, 2018, with the offer launched February 8, 2018. Builds on a 2016 ex-US license for Cx601 (Alofisel), a first-in-class allogeneic stem cell therapy for complex perianal fistulas in Crohn's disease, strengthening Takeda's late-stage GI pipeline with US footprint potential.
Takeda's ~$632M bet on TiGenix's stem-cell therapy Alofisel collapsed: confirmatory trial failed, ~$500M impairment taken, and the drug was pulled from the EU (2024) and Japan (2026) markets.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / TiGenix NV (this deal) | 2018 | $640M | 13 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2018 deals · Takeda Pharmaceutical Company Ltd. deals · Gastroenterology deals